TABLE 3.
Demographic and Clinical Data of Pediatric Treatment Refractory CD
| Patient No. | Age Dx. (yr) | Gender | Duration CD (yr) | PCDAI | Montreal Class* (All Patients A1) |
Medications |
|---|---|---|---|---|---|---|
| 1 | 14.7 | M | 0.4 | 42.5 | L3 B1 | Pred, 6-MP |
| 2 | 10.4 | M | 3.6 | 30 | L3 B2 | Pred, 6-MP |
| 3 | 8.8 | M | 3.5 | 37.5 | L2 B1 | 5-ASA, 6-MP |
| 4 | 9.7 | F | 0.1 | 35 | L3 B1 | Pred. 6-MP |
| 5 | 8.6 | F | 3.0 | 30 | L3 B1 P | Pred, Mtx |
| 6 | 7.2 | M | 0.5 | 55 | L3 B1 P | Pred, 5-ASA, 6-MP |
| 7 | 13.7 | F | 0.1 | 42.5 | L3 B1 | Pred, 6-MP |
| 8 | 15.4 | M | 2.9 | 37.5 | L2 B1 | Budesonide, 5-ASA, 6-MP |
| 9 | 7.6 | M | 2.8 | 30 | L2 B1 | Budesonide, 5-ASA, 6-MP |
| 10 | 10.3 | M | 3.4 | 42.5 | L2 B1 | Budesonide, 5-ASA, 6-MP |
| 11 | 12.6 | M | 0.1 | 30 | L3 B1 | Pred, 5-ASA |
| 12 | 5.6 | M | 3.7 | 42.5 | L2 B1 | Pred, 5-ASA |
| 13 | 15.3 | M | 1.3 | 35 | L3 B1 | Pred, 5-ASA, 6-MP |
| 14 | 15.6 | M | 0.1 | 42.5 | L2 B1 | Pred, 6-MP |
| 15 | 15.6 | M | 0.1 | 30 | L3 B1 | Pred, 5-ASA |
| 16 | 11.4 | F | 0.7 | 37.5 | L3 B2 | Pred, 6-MP |
| 17 | 15.3 | M | 0.1 | 45 | L3 B1 | Pred, 5-ASA |
| 18 | 11.1 | M | 1.6 | 35 | L1 B1 | Mtx, Infliximab |
| 19 | 7.1 | M | 4.3 | 22.5 | L2 B1 | 5-ASA, 6-MP, Infliximab |
| 20 | 13.4 | M | 2.7 | 30 | LI B1 P | 6-MP, Infliximab |
| 21 | 14.8 | F | 3.4 | 25 | L2 B1 | 5-ASA, 6-MP, Infliximab |
| 22 | 12.7 | M | 1.8 | 25 | L3 B1 P | Budesonide, 6-MP |
| 23 | 10.4 | M | 4.4 | 55 | L3 B2 | Pred, Mtx |
| 24 | 15.6 | F | 2.7 | 40 | L1 B2 | Budesonide, 6-MP, Infliximab |
| 25 | 6.4 | F | 7.7 | 52.5 | L3 B1 P | Mtx, Infliximab |
PCDAI, Pediatric Crohn's Disease Activity Index.
*
A1 age ≤16 years old; L1 ileal location, L2 colonic, L3 ileocolonic; B1 nonstricturing, nonpenetrating, B2 stricturing, B3 penetrating, P perianal disease modifier.
Medications: Pred, prednisone; 6-MP, 6-mercaptopurine; 5-ASA, 5-aminosalicylate; Mtx, methotrexate.